Close Menu

NEW YORK – Exact Sciences reported after the close of the market on Thursday that its second quarter revenues rose 35 percent year over year, despite a 34 percent decrease in screening product revenues.

For the three months ended June 30, the Madison, Wisconsin-based molecular diagnostics company reported revenues of $268.9 million, up from $199.9 million a year earlier, beating the average Wall Street estimate of $228.4 million.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.